Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.

被引：22
|
作者：
Gomez-Roca, Carlos Alberto
Cassier, Philippe Alexandre
Italiano, Antoine
Cannarile, Michael
Ries, Carola
Brillouet, Anne
Mueller, Claudia
Jegg, Anna-Maria
Meneses-Lorente, Georgina
Baehner, Monika
Abiraj, Keelara
Loirat, Delphine
Toulmonde, Maud
D'Angelo, Sandra P.
Weber, Kristy
Campone, Mario
Ruettinger, Dominik
Blay, Jean-Yves
Delord, Jean-Pierre
Le Tourneau, Christophe
机构：
[1] Inst Claudius Regaud, Dept Med, Toulouse, France
[2] Ctr Leon Berard, Dept Med, F-69373 Lyon, France
[3] CLCC Inst Bergonie, Bordeaux, France
[4] Roche Pharma Res & Early Dev Oncol, Penzberg, Germany
[5] Roche Pharmaceut Res & Early Dev, Roche Innovat Ctr Penzberg, Penzberg, Germany
[6] Roche Pharmaceut Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland
[7] Roche Pharmaceut Res & Early Dev, Roche Innovat Ctr Welwyn, Welwyn Garden City, England
[8] Inst Curie, Dept Med Oncol, Paris, France
[9] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[11] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[12] Canc Inst West ICO, Nantes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3005
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of RG7155, a novel anti-CSFIR antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).
    Cassier, Philippe Alexandre
    Gomez-Roca, Carlos Alberto
    Italiano, Antoine
    Cannarile, Michael
    Ries, Carola
    Brillouet, Anne
    Mueller, Claudia
    Meneses-Lorente, Georgina
    Baehner, Monika
    Ratnayake, Jayantha
    Harding, Ross
    Abiraj, Keelara
    Gass, Nathalie
    Noh, Karen
    Christen, Randolph D.
    Campone, Mario
    Le Tourneau, Christophe
    Delord, Jean-Pierre
    Ruettinger, Dominik
    Blay, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] PK/PD MEDIATED DOSE OPTIMIZATION OF RG7155, A CSF1R INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS AND PVNS (PIGMENTED VILLONODULAR SYNOVITIS).
    Meneses-Lorente, G.
    Smart, K.
    Broeske, A.
    Ruettinger, D.
    Mueller, C.
    Phipps, A.
    Walz, A.
    Ries, C.
    Baehner, M.
    Cannarile, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S57 - S57
  • [3] Exploratory biomarker program in Phase I clinical development of RG7155, a novel humanized anti-CSF-1R Mab, targeting Tumor Associated Macrophages (TAMs).
    Cannarile, Michael A.
    Habben, Kai
    Heil, Florian
    Broeske, Ann-Marie
    Ruettinger, Dominik
    Culton, Lisa
    Feuerhake, Friedrich
    Ries, Carola H.
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
    Huang, Jing
    Mo, Hongnan
    Wu, Dawei
    Chen, Xuelian
    Ma, Lanying
    Lan, Bo
    Qu, Dong
    Yang, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors.
    Goldman, J. W.
    Gordon, M. S.
    Hurwitz, H.
    Pili, R.
    Mendelson, D. S.
    Adams, B. J.
    Alvarez, D.
    Seon, B. K.
    Theuer, C. P.
    Leigh, B. R.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A PHASE 1 STUDY OF SERPLULIMAB (A NOVEL ANTI-PD-1 ANTIBODY) IN COMBINATION WITH HLX04 (AN ANTI-VEGF ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Guo, Y.
    Li, J.
    Li, Q.
    Xue, J.
    Xue, L.
    Ge, X.
    Lin, F.
    Zhao, W.
    Tang, W.
    Peng, D.
    Wang, Q.
    Zhu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S30
  • [9] A phase I QTc study of tivozanib in patients with advanced solid tumors.
    Chadha, Manpreet Kaur
    Infante, Jeffrey R.
    Cotreau, Monette M.
    Jacobson, Lindsey
    Strahs, Andrew Louis
    Slichenmyer, William
    Vargo, Dennis
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Tolaney, Sara M.
    Hilton, John Frederick
    Cleary, James M.
    Gandhi, Leena
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Wolanski, Andrew
    Bell, Tracy Demeo
    Rodig, Scott J.
    Chiao, Judy H.
    Blake, David
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345